Spotlight On... Allergan ushers #ActuallySheCan campaign onto Tribeca festival screens; J&J beefs up in Africa to drive new growth; Hedge funder takes a $258M hit on merger collapse; and more...

Allergan ($AGN) is taking its hashtag-heavy, emoji-laden female empowerment campaign, #ActuallySheCan, to the Tribeca Film Festival. Three women directors created films featuring three women aiming at big goals, including one who's competing in the famed Iditarod sled-dog race. All three will be screened at the New York-based festival. More from FiercePharmaMarketing

@FiercePharma: WHO fights Angola yellow fever outbreak, global vaccine shortage. More from FierceVaccines | Follow @FiercePharma

@EricPFierce: Unable to find a buyer, Sun will close the Ranbaxy plant in Ireland, lay off 70 remaining workers. FiercePharmaManufacturing report | Follow @EricPFierce

@CarlyHFierce: Valeant's prized GI force, once shielded from job cuts, faces the ax. FiercePharmaMarketing story | Follow @CarlyHFierce

> Johnson & Johnson ($JNJ) is eyeing more growth in Africa, and it's adding new R&D and distribution there to beef up sales of new meds to fight HIV and other diseases common on the continent. Report

> Hedge fund billionaire John Paulson may have suffered a $258 million hit on the collapse of the Pfizer-Allergan merger, harking back to previous losses from a bet on the AbbVie-Shire combo, which also failed because of tax-inversion rule changes. Report

> Amphastar Pharmaceuticals ($AMPH), which has come in for criticism for the price of its overdose antidote naloxone, agreed to give Connecticut a $6 rebate for each dose purchased by a state or municipal agency. Report

> The cost of insulin treatments for diabetes rose by nearly 200% from 2002 to 2013, the Journal of the American Medical Association reports, as expensive new analog treatments supplanted older human insulins. Report

> Hedge funder Bill Ackman is set to explain a 25% quarterly loss to his investors Wednesday, with his bad bet on Valeant Pharmaceuticals ($VRX) first in line. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Warburg-backed Sterigenics buys Nelson Labs to create largest sterilization, testing firm. Article | Follow @FierceMedDev

@EmilyWFierce: ICYMI from FiercePharma: Biogen, Samsung accuse AbbVie of evergreening Humira patents to block biosims. Report | Follow @EmilyWFierce

> Duke University sends recs to FDA for new medical device safety evaluation system. Article

Biotech News

@FierceBiotech: New study highlights a gut pathway for red wine compound resveratrol. More from FierceBiotechResearch | Follow @FierceBiotech

@JohnCFierce: Allergan pivots back to dealmaking as analysts link Pfizer to AbbVie, Biogen and Regeneron. Story | Follow @JohnCFierce

> J&J grabs prostate cancer rights for Tesaro's niraparib in $500M deal. Report

> Apricus wields ax to its pipeline, staff after key testosterone drug fails. Story

> Celltrion, Pfizer win landmark FDA OK for a biosimilar of J&J's blockbuster Remicade. Article

Biotech Research News

> Wistar scientists show impact of aging on melanoma therapy in the lab. Report

> U.S. academics test new mouse model for possible Zika vaccine. More

> Cryoablation therapy used to treat phantom limb pain. Item

> New study highlights a gut pathway for red wine compound resveratrol. Story

> A stem cell therapy trial finally delivers positive results for heart failure. Article

Vaccines News

> Complacency could derail Ebola progress, experts warn. Item

> Experts share info in scramble to fight 'impressive' Zika virus. Report

> WHO fights Angola yellow fever outbreak, global vaccine shortage. Story

> NIAID greenlights funds for adjuvant research. Article

> Genocea reports promising 12-month data for its genital herpes vaccine. More

Pharma Marketing News

> Up up and away: 2015 pharma ad spending ties decade-old record. Item

> Allergan amps up #ActuallySheCan campaign with Tribeca festival film. More

> Boomers are tough on digital pharma ads, but they do like celeb endorsements. Report

> Valeant's prized GI force, once shielded from job cuts, faces the ax. Story

> FDA nitpicks Shiongi's head lice copay voucher over 'false and misleading' claims. Article

And Finally... Worldwide diabetes cases hit 422 million as the disease mushrooms in the developing world. Report

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Johnson & Johnson is chasing giants in its play for psoriatic arthritis with Tremfya. Strong data could help the newcomer convince the FDA.

Besting AbbVie's megablockbuster Humira is no laughing matter, but now Eli Lilly's Taltz has doubled up on head-to-head wins.